Search clinical trials for: Lenvatinib, sintilimab plus SIRT

Total 103 results

Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

Hepatocellular Carcinoma

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Sun Yat-sen University

Not yet recruiting

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Non Clear Cell Renal Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

Advanced or Metastatic Solid Tumors

China
Shanghai Changzheng Hospital

Completed

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

Colorectal Cancer | Immunotherapy | Sintilimab | First-line Treatment | Anlotinib | Chemo-free Therapy

China
Mian XI

Recruiting

Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01) (ISBRT01)

Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

Gastric Cancer

China
Shandong Cancer Hospital and Institute

Recruiting

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Pancreas Cancer

China
National Taiwan University Hospital

Not yet recruiting

Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.

Unresectable Hepatocellular Carcinoma | Pembrolizumab | Stereotactic Body Radiotherapy | Lenvatinib

Taiwan
Fudan University

Recruiting

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Fudan University

Recruiting

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

NSCLC Stage IV

China
Tianjin Medical University Cancer Institute and...

Recruiting

Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

China
Second Affiliated Hospital of Guangzhou Medical...

Completed

TACE Combined With Lenvatinib and Sintilimab for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

DLBCL

China
Jun-Lin Yi, MD

Not yet recruiting

Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC) (LM-HNSCC)

Head and Neck Squamous Cell Carcinoma | Immunotherapy | Metastases | Stereotactic Body Radiotherapy

China
The First Hospital of Jilin University

Recruiting

Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Lung Cancer

China
Fudan University

Completed

Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC

Esophageal Squamous Cell Carcinoma

China
Sun Yat-sen University
Fifth Affiliated Hospital, Sun Yat-Sen University; Ningbo Medical Center Lihuili...

Not yet recruiting

Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402) (HSBRT2402)

Hepatocellular Carcinoma

China
Ospedale Generale Di Zona Moriggia-Pelascini

Unknown

Effectiveness of Different Approaches for the Rehabilitation of Gait in Patients With Parkinson's Disease (Tr-T-VR)

Rehabilitation | PD | Gait Dysfunction, Neurologic

Italy
Peking Union Medical College Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Xinrui Zhu

Enrolling by invitation

The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable | Tyrosine Kinase Inhibitor | Transarterial Chemoembolization | Immune Checkpoint Blockade

China
Sichuan University
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

Stage IV NSCLC

China
Peking Union Medical College Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

Advanced Biliary Tract Cancer

China
Chen Xiaoping

Not yet recruiting

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

HCC
Fudan University

Recruiting

Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)

Advanced Intrahepatic Cholangiocarcinoma

China
Fudan University

Recruiting

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08） (CASTLE-08)

Advanced Biliary Tract Cancer

China
Baocai Xing

Recruiting

Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Beijing Tsinghua Chang Gung Hospital

Recruiting

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Hepatocellular Carcinoma

China
Fudan University

Recruiting

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

Intrahepatic Cholangiocarcinoma

China
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)

Advanced Renal Cell Carcinoma
Yunfei Yuan

Recruiting

TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial (Thalen)

Hepatocellular Carcinoma | Transarterial Chemoembolization

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Zhejiang University

Recruiting

Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1 (TACTIC)

Locally Advanced Gastric Carcinoma

China
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-013)

Cholangiocarcinoma Non-resectable

China
Tongji Hospital
Geneplus-Beijing Co. Ltd.

Recruiting

Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-011)

Hepatocellular Carcinoma Non-resectable

China
Shanghai Chest Hospital

Unknown

Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

Carcinoma | Non-small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy...

Recruiting

FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage

Colorectal Neoplasms Malignant

China
Hunan Province Tumor Hospital

Recruiting

Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer

China
Tongji Hospital
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-012)

Cholangiocarcinoma Non-resectable

China
Huazhong University of Science and Technology

Active, not recruiting

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

Patients With Advanced Metastatic Colorectal Cancer

China
Juravinski Cancer Center
Hamilton Health Sciences Corporation; Juravinski Cancer Centre Foundation

Unknown

Stereotactic Body Radiotherapy Boost After Palliative Radiotherapy for Spinal Cord Compression (CRUSSH)

Spinal Cord Compression | Cauda Equina Syndrome | Stereotactic Body Radiotherapy

Canada
Sun Yat-sen University

Recruiting

Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis

ICC

China
Nanfang Hospital of Southern Medical University

Not yet recruiting

Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University

Recruiting

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Gastric Cancer

China
Fudan University

Recruiting

Cryoablation Combined With Sintilimab Plus Lenvatinib In Previously Treated Unresectable Liver Metastasis From Solid Tumors

Liver Metastasis

China
Ruijin Hospital

Recruiting

Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer

HER2-negative Advanced Gastric Cancer

China
Hospital of Macerata

Recruiting

International Multicentric Study ARON-1

Metastatic Renal Cell Carcinoma (mRCC)

Italy
Fudan University

Recruiting

PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC

Hepatocellular Carcinoma

China
Peking Union Medical College Hospital

Completed

Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

Cholangiocarcinoma | Biomarker | Combinational Immunotherapy | Liver Neoplasm Malignant Primary

China
Third Affiliated Hospital, Sun Yat-Sen University

Recruiting

TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC

Hepatocellular Carcinoma

China

3

Subscribe